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Abstract
Background: The frequent occurrence of chemoresistant strains reduces the chances of eradication of H. pylori
infection and prompted the investigation of non-antibiotic substances active against this organism. Some
surfactants enhance the effectiveness of antibiotics for their permeabilizing properties towards bacteria. We
examined the antimicrobial activity to H. pylori of the surfactant polysorbate 80, used alone and in association with
amoxicillin, clarithromycin, metronidazole, levofloxacin and tetracycline. We also aimed to study the ultrastructural
alterations caused upon H. pylori by polysorbate 80, alone and in combination with antibiotics. Twenty-two H. pylori
strains were tested using the broth dilution method. After incubation, broth from each dilution was subcultured
onto agar enriched with foetal bovine serum to determine the minimum bactericidal concentration (MBC).
Synergistic effect of polysorbate 80 with antibiotics was investigated by the broth dilution and disc diffusion
techniques. Ultrastructural alterations of organisms treated with polysorbate 80, alone and in association with
antibiotics were analyzed by transmission electron microscopy.
Results: MBCs of polysorbate 80 ranged from 2.6 (1.1) μg/ml to 32 (0) μg/ml. Polysorbate 80 exerted a synergistic
effect when associated with metronidazole and clarithromycin: polysorbate 80 and metronidazole MBCs decreased
by≥ 4 fold; clarithromycin MBCs for two resistant strains decreased by 20 and 1000 times. The principal alteration
caused by polysorbate 80 consisted in the detachment of the outer membrane of bacteria.
Conclusions: The bactericidal activity of polysorbate 80 and the synergistic effect of the association with
metronidazole and clarithromycin could be useful in the treatment of H. pylori infection.
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Background
Helicobacter pylori is a microaerophilic gram-negative
helical-shaped bacterium that infects approximately 30%
of the population in developed countries and up to 90%
of the population in developing countries [1,2].
The standard treatment of H. pylori infection, triple
therapy, consists of two antibiotics and a proton pump
inhibitor (PPI), or ranitidine bismuth citrate, adminis-
tered for one or two weeks [3,4]. Amoxicillin, clarithro-
mycin (or azithromycin), imidazoles (metronidazole or
tinidazole), levofloxacin and tetracycline are the antibio-
tics used in the first and second line treatments. Options
for third and subsequent line therapies include rifabutin
and furazolidone-based regimes [5].
Recent protocols, such as the so-called sequential ther-
apy, seem more successful than triple therapy; such
treatment employs three antibiotics and a PPI and lasts
for 10 days [6]. In 2011, Malfertheiner et al. [7] proposed
a quadruple therapy (two antibiotics, tetracycline and
metronidazole, PPI and bismuth) as a first line treatment
because of the increasing prevalence of clarithromycin
resistant strains.
Treatment failure is observed in 10%-23% of patients
[4,8] and is mainly due to loss of antibiotic efficacy; in
particular, the worldwide H. pylori antibiotic resistance
rates in 2010 were 17.2% for clarithromycin, 26.7% for
metronidazole, 11.2% for amoxicillin, 16.2% for levoflo-
xacin, 5.9% for tetracycline and 9.6% for multiple antibio-
tics [9]. This dramatic fall in the eradication rates [10]
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strongly indicates the need to improve current thera-
peutic strategies and to develop new drugs, such as non-
antibiotic substances [11-13]. Vitor and Vale [14]
reviewed the study of alternative therapies, mainly pro-
biotics and phytomedicine, for H. pylori infection. Pro-
biotics attenuate the side effects of antibiotics and
improve their efficacy; some plant extracts possess anti-
H. pylori properties [14], but in this case, the active com-
ponent should be identified, the mechanism of action
and the potential toxicity for the patient explored, finally
the possible resistance against these new phytotherapeu-
tic agents addressed.
Among the numerous compounds with potential anti-
bacterial properties, polysorbates, a class of substances
derived from sorbitan, known with the commercial
name of TweenW, are particularly appealing. In particu-
lar, polysorbate 80 is a nonionic surfactant used as an
emulsifier in food, for example ice cream (where it is
employed in concentrations of up to 0.5%). It is also
used in bacterial broth cultures to prevent foam forma-
tion and as an excipient in numerous medications and
vaccines against influenza to stabilize aqueous formula-
tions. It is reputed to be a generally safe and well-tolerated
compound.
These substances, in particular Tween 80, have
been employed for their nature of surfactant to pro-
duce microemulsion systems with glycerol monolau-
rate as oil and organic acids as co-surfactant; such
microemulsions caused a complete loss of viability of
Staphylococcus aureus and Escherichia coli [15]. The
potential antimicrobial activity of Tweens alone, how-
ever, was not explored. Other surfactants, such as
dodecyl maltoside and octyl glucoside, enhanced the
effectiveness of antibiotics used in the treatment of
human pulmonary tuberculosis for their permeabiliz-
ing properties [16]. Finally, Huesca et al. [17] exam-
ined some substances, included Tween detergents,
considered, in the past, efficacious treatments for
peptic ulcer, and found that they were able to inhibit
H. pylori receptor binding in vitro.
All these observations suggest that detergents could
be useful in the treatment of H. pylori infection,
although their potential antibacterial activity against
H. pylori has not been examined yet. The aims of this
study were: a) to determine the antimicrobial activity
against H. pylori of polysorbate 80 and antibiotics
most commonly used to eradicate H. pylori infection:
amoxicillin, clarithromycin, metronidazole, levofloxa-
cin and tetracycline; b) to find out whether the associ-
ation of polysorbate 80 with antibiotics could increase
their activity; c) finally, to investigate on the possible
ultrastructural morphological alterations exerted upon
H. pylori by polysorbate 80 (alone and in associations
with clarithromycin and metronidazole), which could
help explaining its mechanism of action.
Results
Characteristics of strains tested
The 22 strains tested include the different genotypes of
H. pylori (i.e. cagA-positive or –negative) and different
source of isolation, i.e. from patients with chronic gastri-
tis only (CGO), duodenal ulcer (DU) and gastric carci-
noma (GC). Fifteen strains were primary strains (that is
isolated from patients naïve for eradication treatment),
seven strains, isolated from patients unsuccessfully trea-
ted with the triple therapy, were named as secondary.
The strain characteristics are reported in Table 1. Out of
the 22 strains tested, six strains were isolated from
patients with GC, three strains from cases of DU and
the others from patients with CGO. Sixteen strains pos-
sessed the cagA gene; strain 328 Km was a cagA-negative
isogenic mutant of the wild cagA-positive isolate 328
(Table 1).
Determination of the chemosusceptibility of H. pylori
strains to polysorbate 80 and antibiotics
The results of the chemosusceptibility tests are expressed
in μg/mL and are reported in Table 2 as mean and stan-
dard deviation in parentheses. MBCs of polysorbate 80
ranged from 2.6 (1.1) to 32 (0) (Table 2); the MBC50 (the
Table 1 Characteristics of H. pylori strains tested
Parameter Helicobacter pylori strains
CCUG
17874


















CGO CGO CGO GC DU GC CGO CGO CGO CGO CGO DU GC CGO DU GC CGO GC GC CGO CGO CGO
Primary
strain
Yes Yes Yes Yes Yes Yes Yes Yes No No No No Yes No Yes Yes Yes Yes Yes Yes No No
* This is an isogenic cagA negative mutant of the wild strain 328.
CGO: chronic gastritis only; DU: duodenal ulcer; GC: gastric carcinoma.
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Table 2 MBCs of polysorbate 80, antibiotics and association of polysorbate 80 and antibiotics to the H. pylori strains tested; the values are expressed in μg/ml
and reported as mean and standard deviation in parentheses
Drugs Helicobacter pylori strains
CCUG
17874





16 (0) 8 (0) 13.3
(4.6)




32 (0) 16 (0) 13.3 (4.6) 16 (0) 16 (0) 8 (0) 16 (0) 8 (0) 2.6 (1.1) 10.6
(4.6)
8 (0) 6.6 (2.3) 16 (0)




0.01 (0) 0.005 (0) 0.01 (0) 0.07
(.02)
0.6 (.1) 0.1 (.04) 0.5 (0) 0.03 (0) 0.06 (0) 0.05
(.02)
0.04 (0) 0.08 (0)
Clarithromycin 0.25 (0) 0.01 (0) 0.01 (0) 0.08 (0) 0.08 (0) 0.11
(.05)




0.04 (0) 0.04 (0) 32 (0) 0.11
(.05)




32 (0) 64 (0)










Levofloxacin 0.32 (0) 0.27
(.09)
0.32 (0) 0.16 (0) 0.16 (0) 0.32 (0) 0.13
(.05)
0.16 (0) 0.25 (0) 0.32 (0) 0.16 (0) 0.32 (0) 0.13 (.05) 0.32 (0) 0.16 (0) 0.25 (0) 0.21
(.07)
0.12 (0) 0.5 (0) 2 (0) 0.25 (0) 0.21
(.07)
Tetracycline 2.0 (0) 0.25 (0) 1.67
(.58)
1.0 (0) 0.06 (0) 2.0 (0) 0.03 (0) 0.04
(.02)
0.06 (0) 0.06 (0) 0.25 (0) 0.25 (0) 0.05 (.02) 4 (0) 6.6 (2.3) 0.25 (0) 0.67
(.29)



































































































































































































































































































concentration at which ≥50% of strains were killed) was 16
(0). All strains were susceptible to amoxicillin (< 1.0 μg/ml)
and MBCs ranged from 0.002 (0) to 0.6 (0.1); the MBC50
was 0.03 (0) (Table 2). Five secondary isolates (23.9%), were
resistant to clarithromycin (> 1.0 μg/ml) (Table 2). Two
strains presented a high level of resistance with MBC of
320 (0) and 2500 (0), while MBC of the other strains were
32 (0) for two strains and 64 (0) (Table 2). MBCs for the
susceptible strains ranged from 0.01 (0) to 0.5 (0) (Table 2)
and the MBC50 was 0.08 (0). Eight strains (36.3%, four
strains were secondary) were resistant to metronidazole
(>4 μg/ml) (Table 2); MBCs for resistant strains were 20.8
(7.2), 21.3 (9.2), 26.6 (9.2), 32 (0), 64 (0), 128 (0) for two
strains and 170.6 (73.9) (Table 2). All strains, excepted one
primary strain, were susceptible to levofloxacin (<2 μg/ml)
(Table 2); MBCs ranged from 0.12 (0) to 0.5 (0) and the
MBC50 was 0.25 (0) (Table 2). Finally, one primary and
one secondary strains (9.0%) were resistant to tetracycline
with MBC of 4 (0) and 6.6 (2.3); one strain was also resis-
tant to metronidazole and clarithromycin, the other strain
to metronidazole only. MBCs of tetracycline for the sus-
ceptible strains (< 4 μg/ml) ranged from 0.03 (0) to 2 (0)
and the MBC50 was 0.25 (0).
Determination of the chemosusceptibility of H. pylori
strains to polysorbate 80 used in association with
clarithromycin or metronidazole
The combination of polysorbate 80 with metronidazole
increased the size of the growth inhibition halos (Figure 1);
around the disk containing polysorbate 80, a minimal halo
of complete inhibition of growth, ~1 mm, can be seen.
Subculture tests showed the presence of another halo of
about 4 mm contains developed dead bacteria. The same
effect was observed when clarithromycin was assayed
alone and with polysorbate 80 (data not shown). Halo
sizes around discs charged with polysorbate 80 and
amoxicillin, or levofloxacin, or tetracycline were not larger
than those obtained with single antibiotics (data not
shown). The synergistic effect of the association polysor-
bate 80/clarithromycin and polysorbate 80/metronidazole
was confirmed by the broth dilution tests (Table 2). When
used in association, the MBCs of polysorbate 80 decreased
by 2–4 times and those of antibiotics by 2–16 times, com-
pared to the respective MBCs of drugs used alone. The
effect of the association of polysorbate 80 with amoxicillin,
or levofloxacin, or tetracycline was negligible (Table 2).
TEM analysis of CCUG 17874 and C/M-R2 H. pylori strains
treated with polysorbate 80, alone and in association
with clarithromycin and metronidazole
The ultrastructural characteristics of the two untreated
strains appeared different from each other. CCUG
17874H. pylori organisms showed homogeneous cyto-
plasm and rare detachment membrane/cytoplasm
(Table 3, Figure 2A); ~ 5% of cells presented an altered
profile. C/M-R2 organisms showed homogeneous cyto-
plasm and vesicles (Figure 2B). In both strains, flagella
have been observed (Table 3).
To examine the ultrastructural characteristics of the
organisms treated with the studied substances, the bac-
teria were incubated overnight with the single drugs and
with antibiotics associated with polysorbate 80 at con-
centrations corresponding to the respective MBCs. In
both strains treated with polysorbate 80 (Table 3), we
observed swollen bacteria and alterations of the outer
membrane (Figures 2C, 2D), particularly evident in CCUG
17874H. pylori strain. The cytoplasm showed a typical
granular texture; in both strains, we noted the presence of
vesicles, which were more numerous in C/M-R2 strain.
The two strains challenged with clarithromycin showed
different ultrastructural alterations. CCUG 17874H. pylori
strain (Figure 2E) was characterised by altered forms with
typical “holes” in the cytoplasm and detachment of the
inner membrane from the cytoplasm or cytoplasm retrac-
tion; flagella were observed, whereas vesicles were absent
(Table 3). In C/M-R2 strain the morphology was con-
served in about half of the analyzed bacteria (Figure 2F),
whereas ~ 40% of cells showed granular cytoplasm and
~ 35% altered outer membrane. Flagella were observed
and vesicles were present in C/M-R2 strain only (Table 3).
As far as the strains assayed with metronidazole are
concerned, CCUG 17874 strain was characterised by
organisms with severely altered shape and peculiar
detachments between membrane and cytoplasm that
often appeared fragmented (Figure 2G); flagella and vesi-
cles were not observed in the sample (Table 3). C/M-R2
strain did not show any peculiar ultrastructural altera-
tions after metronidazole treatment (Figure 2H).
Figure 1 The combination of polysorbate 80 with
metronidazole (disc on the right) increases the size of the
growth inhibition halo; the disc on the left was charged with
metronidazole alone and the disc at the top with polysorbate
80 alone.
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In the samples treated with both polysorbate 80 and
clarithromycin, the shape was altered in both bacterial
strains and the synergic effect of the two compounds
was evident (Figures 2I, 2J). The examination of CCUG
17874 strain revealed swollen cells, granular cytoplasm
and altered outer membrane, typical alterations induced
by polysorbate 80, together with detachment of the inner
membrane from the cytoplasm and “holes” in the cyto-
plasm, typical effect of clarithromycin (Table 3). Flagella
and rare vesicles were observed. C/M-R2 strain showed
swollen bacteria with cytoplasm that gradually had lost
its homogeneity; numerous vesicles and rare fragments
of flagella were present (Table 3). The examination of
CCUG 17874 strain treated with polysorbate 80 and
metronidazole (Figure 2K) showed swollen bacteria with
non-homogeneous cytoplasm, presence of vesicles (typical
features of polysorbate 80 treatment) concomitant with pe-
culiar detachments of the membrane from cytoplasm that
often appeared fragmented (typical alterations caused by
metronidazole). Vesicles were present, flagella were not
observed (Table 3). C/M-R2 strain showed swollen bacteria
with granular cytoplasm and the presence of vesicles
(Figure 2L), all characteristics typical of polysorbate 80
treatment (Table 3); no flagella were found.
Discussion
Chemoresistances are the main cause of therapeutic fail-
ure of H. pylori infection [18]. The occurrence of acquired
resistances in such species is very high, because of certain
characteristics that make H. pylori hypermutable [19].
Mutation rates in H. pylori are in fact 10–700 fold higher
than that observed in other species, for instance
Escherichia coli; in addition, the mechanisms of acquired
chemoresistance in H. pylori include its significant genetic
competence (i.e. the ability to recombine exogenous
DNA) [19]. Stress conditions, such as the antibiotic
treatment and the exposure to the gastric acid, induce nu-
merous events in this species, which may end up enhan-
cing the frequency of chemoresistances: a) the
transcription and translation of natural competence genes,
which increase the frequency of transformation; b) the
transcription of a lysozyme-like protein, which promotes
DNA donation from the neighbouring cells; c) the stimu-
lation of DNA uptake machinery, which increases the im-
port of foreign DNA [20]. An additional source of genetic
exchange is the transfer of genomic islands by conjugative
mechanisms [21]. If we consider that the antibiotics
utilizable in the treatment of H. pylori infection are limited
and that it is mandatory to use them in combination of
two or three at a time to be efficacious, the obvious
conclusion is that in a few years physicians might lack
effective antibiotics.
These observations prompted various researchers to
investigate non-antibiotic compounds for their anti-
microbial activity against H. pylori. Phytomedicine holds
great promise for the treatment of H. pylori infection;
however, it did not overcome the problem of resistance
to the current antibiotics, nor has potentiated the anti-
biotic treatment [22]. The results of the present study
showed that polysorbate 80 is bactericidal towards H.
pylori with MBCs that could easily be achieved in the
stomach. In addition, experiments in animals have esta-
blished that polysorbate 80’s toxic dosages are very high:
the equivalent toxic dosage for human beings is > 350 g
a day for three days [23]. The best demonstration that
such substance is safe and well tolerated comes from the
observation that it became part of most foods in Europe
and America, where each person ingests about 100 mg
of polysorbate 80 in foods per day [24].
As polysorbate 80 is a detergent, it is likely that it exerts
an antimicrobial activity against H. pylori by reacting with
the bacterial outer membrane. Thus, in order to shed light
Table 3 Approximate percentages of organisms showing ultrastructural alterations observed in two H. pylori strains
after treatment with polysorbate 80, clarithromycin, metronidazole, polysorbate 80/clarithromycin and polysorbate
80/metronidazole


























% Altered Shape 5 3 90 60 85 50 85 5 100 95 85 80
% Granular Cytoplasm 1 3 90 70 10 40 5 5 75 60 70 65
% Altered outer membrane 1 1 75 75 20 35 20 1 70 75 70 75
% Presence of “holes” in the
cytoplasm
0 0 1 0 40 2 2 1 20 1 1 15
% Detachment membrane/
cytoplasm
3 1 10 2 30 2 60 2 25 2 50 10
% Presence of flagella YES YES NO YES YES YES NO YES YES YES NO NO
% Presence of vesicles - + ++ ++++ - ++ - + +/− ++++ ++ ++
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Figure 2 (See legend on next page.)
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upon its mechanism of action, we examined by TEM
strains exposed to polysorbate 80, alone and associated
with metronidazole and clarithromycin, the two antibio-
tics with which it showed a synergistic effect.
The observed morphological alterations in all samples
treated with polysorbate 80 are conceivably caused by
the detergent properties of this compound. Every time
the bacteria have been treated with polysorbate 80, ty-
pical and recurrent ultrastructural anomalies have been
detected, namely alterations of the bacterial shape, swe-
lling of the organisms, loss of the normal and homoge-
neous cytoplasmic structures, anomalies in the bacterial
envelope especially in the outer membrane and the pre-
sence of numerous vesicles. In the CCUG 17874 strain
the vesicles were detectable only after polysorbate 80
treatments, used alone and in combination with antibiotics.
Different is the situation for the M/C-R2 strain, in which
the vesicles were present in the control (untreated) samples,
but they became more numerous in the treated specimens.
The ability of some H. pylori strains to naturally produce
vesicles is well known [25]; however, after treatment of this
strain with polysorbate 80, the number of vesicles definitely
increased. The vesicles most likely originate from the outer
membrane of bacteria: in the presence of detergents, the
phospholipid bilayer is disrupted and micellae-like struc-
tures are produced. It is noteworthy that in both strains
treated with polysorbate 80 we observed similar ultrastruc-
tural alterations, such as swelling of the organisms, altera-
tions of the outer membrane and cytoplasm and presence
of vesicles. A different behaviour of both strains was
detected after treatment with antibiotics. Clarithromycin
induced peculiar ultrastructural alterations in CCUG 17874
strain, namely typical “holes” in the cytoplasm, whereas in
C/M-R2 strain we observed organisms with granular cyto-
plasm and altered envelopes. Similar modifications were
described in strains treated with a different macrolide,
erythromycin [26]. Metronidazole caused severe alterations
in CCUG 17874 strain whereas it did not alter the normal
morphology in the C/M-R2 strain, as also observed by
Armstrong et al. [26].
In the specimens treated with antibiotics in association
with polysorbate 80, the bacteria showed a combination
of ultrastructural anomalies typical of the organisms
challenged separately with the antibiotics, but at concen-
trations reduced by approximately four-times.
The observation of a synergistic effect of polysorbate
80 associated with metronidazole and clarithromycin
deserves some comments. We have observed a reduction
of metronidazole’s MBCs when the drug was associated
with polysorbate 80, independently of whether strains
were metronidazole susceptible or resistant. It is likely
that the mechanism of synergy consists in an increased
influx or improved bioavailability of such chemotherapic,
determined by the damage of the outer membrane
exerted by polysorbate 80 (as shown by TEM). This inter-
pretation is supported by the observation that resistance
to metronidazole might be overcome with increased
doses of drug [27].
Out of the eight metronidazole resistant strains used to
evaluate the outcome of associations, in three cases, poly-
sorbate tested with metronidazole reduced the MBCs of
the chemoterapic to concentrations at which strains can
be considered susceptible, i.e. ≤ 4 μg/mL. The main me-
chanism of metronidazole resistance in H. pylori consists
in mutations in rdxA and frxA genes, which encode an
NADPH nitroreductase and an oxidoreductase, respec-
tively [28]; the drug has to be reduced by bacterial reduc-
tive enzymes to exert its antimicrobial activity. Some
researchers, however, claim that the first step to the deve-
lopment of metronidazole resistance consists in the over-
expression of hefA gene, which encodes for an efflux
pump [29]. Efflux pumps are very common amongst bac-
teria, including H. pylori, and protect them from the pos-
sible toxic effects of metabolite or antibiotic accumulation
[30,31]. One component of a family of multidrug efflux
transporters [32], widespread only among Gram-negative
(See figure on previous page.)
Figure 2 TEM micrographs of CCUG 17874 (A, C, E, G, I, K) and M/C-R2 (B, D, F, H, J, L) H. pylori strains. CCUG 17874 untreated bacteria
(Figure 2A) show homogeneous cytoplasm and rare membrane/cytoplasm detachments (arrow). M/C-R2 untreated bacteria (Figure 2B) show
homogeneous cytoplasm, flagella and vesicles (arrow). CCUG 17874 bacteria treated with polysorbate 80 (Figure 2C) are swollen and
morphologically altered; cytoplasm is granular and detached from the inner membrane (arrow head); vesicles (arrow) are present. M/C-R2 bacteria
treated with polysorbate 80 (Figure 2D) are swollen and morphologically altered; cytoplasm is not homogeneous and numerous vesicles are
present (arrow). CCUG 17874 bacteria treated with clarithromycin (Figure 2E) show altered shape, typical “holes” in the cytoplasm (arrow head),
membrane/cytoplasm detachment (arrows) and fragments of flagella. Some M/C-R2 organisms treated with clarithromycin (Figure 2F) have a
conserved morphology, others show granular cytoplasm and altered membranes. Flagella and vesicles (arrows) are present. CCUG 17874 bacteria
incubated with metronidazole (Figure 2G) are severely altered and show detachment of cytoplasm, often fragmented, from inner membrane
(arrows). M/C-R2 bacteria treated with metronidazole (Figure 2H) are morphologically similar to control. CCUG 17874 treated with polysorbate 80
and clarithromycin (Figure 2I) displays alterations typical of organisms treated with the two substances used alone: swollen cells and detachment
membrane/cytoplasm (arrow). M/C-R2 bacteria treated with polysorbate 80 and clarithromycin (Figure 2J) are mostly swollen, their cytoplasm is
granular and numerous vesicles are present (arrows). CCUG 17874 strain treated with polysorbate 80 and metronidazole (Figure 2K) displays
swollen bacteria, granular cytoplasm, presence of vesicles (arrows) and detachment of fragmented cytoplasm from the inner membrane (arrow
head). M/C-R2 bacteria treated with polysorbate 80 and metronidazole (Figure 2L) are swollen; cytoplasm is granular and displays the presence of
“holes”. Vesicles are present (arrows). Bars 2A-L: 1000 nm.
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bacteria, is localised in the outer membranes [33]. Since it
has been shown that the inactivation of any constituent of
the efflux mechanism can abrogate the function of the en-
tire group of efflux systems [29], we have speculated that
the damage of the outer membrane exerted by polysorbate
80 could have caused the loss of such efflux transporter in
our strains, thus impairing the mechanism of resistance.
The strains still resistant to metronidazole even after treat-
ment with polysorbate 80 could also have undergone a
mutation of the reduction systems, i.e. it had a double
mechanism of resistance.
The increased susceptibility to clarithromycin used in
combination with polysorbate 80 could also be due to an
augmented permeability of membranes exerted by the
detergent. The main constituent of the outer membrane
in Gram-negative bacteria is lipopolysaccharide (LPS); it
coats the cell surface and works to exclude large hydro-
phobic compounds, such as antibiotics, from invading
the cell. LPS has a significant role in membrane trans-
port: the lipid compositions of LPS and the associated
proteins have a strong impact on the sensitivity of bac-
teria to many types of antibiotics [34]. Unlike small
hydrophilic antibiotics, large lipophilic agents, such as
macrolides, have difficulty in diffusing through the LPS.
Previous studies indicate that membrane permeabilizers,
such as Tris/EDTA, polymyxin B etc., have the ability to
increase the levels of antibiotic inflow [34] and conse-
quently the sensitivity of Gram-negative bacteria to
hydrophobic antibiotics, including macrolides [35,36]. In
this study, two strains were highly resistant to clarithro-
mycin, with MBCs of 320 μg/mL and 2500 μg/mL. In
the presence of polysorbate 80, clarithromycin’s MBCs
decreased by 16 times and 1000 times, respectively,
i.e. to 20 μg/mL and 2.5 μg/mL, which still are in the
range of resistant values (threshold = 1 μg/mL). In these
cases, we hypothesize the concomitance of two mechan-
isms of resistance. In a large number of bacterial species,
in fact, the existence of drug-resistant strains is due to
modifications in the lipid or protein composition of the
outer membrane, which work in synergy with other re-
sistance mechanisms [34]. Point mutations in 23S rRNA
normally account for the development of resistance to
clarithromycin in H. pylori and reduce the chances of
eradication when the classical triple therapy is employed
[37]. It is likely that in our strains the presence of an efflux
apparatus cooperates with putative 23S rRNA mutations
to make these two strains highly resistant to clarithromy-
cin [38]. Polysorbate 80 conceivably increased their sensi-
tivity by destroying the outer membrane; strains, however,
were still resistant because of the existence of another pu-
tative mechanism, such as ribosome mutation.
A plausible explanation for the observation that the as-
sociation of polysorbate 80 with amoxicillin, levofloxacin
and tetracycline was not synergistic may consist in the
sizes and hydrophilic nature of antimicrobials. Macromo-
lecules such as clarithromycin, which hardly penetrate
into bacteria using the lipid layer, exploit the alterations of
the bacterial outer membranes to diffuse into microorga-
nisms. Small hydrophilic antibiotics, such as β-lactams,
tetracycline, fluoroquinolones etc., use porin channels to
cross the outer membrane and diffuse very well [39]. For
this reason, they do not take advantage by the disruption
of membranes; thus their association with polysorbate 80
is indifferent.
Conclusions
In conclusion, polysorbate 80 shows a bactericidal activity
against H. pylori and exerts a synergistic effect with some
chemotherapics. We therefore propose such compound




The 22 strains used are listed in Table 1. The whole
study was conducted following the approval of the local
University Hospital Ethics Committee. All patients gave
a written informed consent prior to inclusion of strains
isolated from them in the study. Bacterial suspensions
were stored in glycerol broth at −80°C until the MBC
determination was carried out. Suspensions were thawed
and subcultured twice in selective Brucella agar plates
(Pylori plates, BioMérieux, Italia S.p.A., Rome, Italy.)
containing 10% foetal calf serum and 10 mg/L of each
vancomycin, trimethoprim, and amphotericin B and
5 mg/L of cefsulodin. Plates were incubated in jars with
a microaerobic environment generated using Campy Pak
sleeves (Oxoid Ltd., Basingstoke, England).
Polysorbate 80 and antibiotics -amoxicillin, clarithro-
mycin, metronidazole, tetracycline and levofloxacin-
(Sigma Aldrich-Milan, Italy) were dissolved in sterile
water containing (when necessary) 4% of DMSO, steri-
lized by filtration and double diluted in Brucella broth
containing 10% foetal calf serum, 10 mg/L of each
vancomycin, trimethoprim, and amphotericin B and
5 mg/L of cefsulodin (to avoid contaminations). One
microwell contained plain broth and was the control.
Tests were carried out in triplicate in a final volume of
0.1 mL, using MicrotiterW plates. H. pylori suspensions
were prepared starting from cultures on Brucella agar
with 10% foetal calf serum incubated in a microaerobic
environment for 48 h. The bacterial suspensions were
then added to each microwell at a final concentration of
approximately 106 colony-forming units per mL. After
24 h of incubation under microaerobic conditions at
37°C, 3 μL of broth from each dilution were deposited
onto Brucella agar plates, which were incubated for 3–
5 days in a microaerobic atmosphere at 37°C. The lowest
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concentration in broth, for which the subculture on agar
showed complete absence of growth, was considered the
MBC. Results are the average of three determinations.
Determination of antimicrobial activity of polysorbate 80
associated with antibiotics
Tests to evaluate the possible synergistic effect of poly-
sorbate 80 associated with antibiotics were performed
on all strains. Two methods have been used, the disc di-
ffusion and the broth dilution techniques. Briefly, blood-
agar plates were seeded using a swab with a suspension
of the type strain CCUG 17874 or the strain C/M-R2,
whose density corresponded to McFarland no. 4 opacity
standard. After the surface was dried, three paper discs
were deposited on each plate, one disc was charged with
the antibiotic (amoxicillin 2 μg, clarithromycin 15 μg,
metronidazole and levofloxacin 5 μg each and tetracyc-
line 10 μg), one with polysorbate 80 (0.4 mg) and the
third one with both drugs, polysorbate 80 and antibiotic,
at the same concentration present in the discs charged
with single antibiotics. After a 3-day incubation in
microaerobic environment at 37°C, plates were inspected
and the halos of growth inhibition measured. The broth
dilution test was carried out as follows: after the first
drug was diluted, the second drug was added to each
well of the first row containing different concentrations
of the first compound; afterwards, the dilution of the
second compound was carried out. Concurrently, we
determined the MBC of the single substances. Tests
were performed in triplicate.
Ultrastructural analysis of H pylori with transmission
electron microscopy (TEM)
For the ultrastructural analysis two strains of H. pylori
were used: CCUG 17874 (metronidazole resistant type
strain, isolated from a chronic gastritis case) and C/M-
R2 (clarithromycin resistant clinical strain isolated
from a chronic gastritis case). These two strains were
treated with: 1-polysorbate 80, 2-clarithromycin, 3-
metronidazole, 4- polysorbate 80 and clarithromycin,
5- polysorbate 80 and metronidazole. The other anti-
biotics were not tested because they did not exert any
synergistic effect when examined in association with
polysorbate 80.
The bacterial suspensions, after overnight incubation
with the drugs at the concentrations corresponding to
the respective MBCs and MBCs of their associations,
were washed in phosphate-buffered saline (PBS), fixed in
cold Karnovsky fixative and maintained at 4°C for 2 h.
Fixed organisms were washed in 0.1 mol/L cacodylate
buffer (pH 7.2) for 12 h at 4°C and postfixed in 1% buf-
fered osmium tetroxide at 4°C for 1 h. Then the samples
were washed in 0.1 mol/L cacodylate buffer (pH 7.2) for
at least 2 h at 4°C, dehydrated in a series of ethanol
(50%, 75%, 95%, 100%), exchanged through propylene
oxide and embedded in Epon Araldite. Ultra-thin sec-
tions were obtained with a Supernova ultramicrotome
(Reickert Jung, Vienna, Austria) with diamond knife,
mounted on copper grids, stained with uranyl acetate
and lead citrate and observed and photographed with a
Philips EM208 TEM (Philips Scientifics, Eindhoven, The
Netherlands).
A minimum of 500 bacteria per sample were analyzed
and the anomalies related to the bacterial morphology
(altered shape), the cytoplasm texture (granular cyto-
plasm, “holes” in the cytoplasm), the envelopes (altered
envelopes, outer membrane detachment from the cell
wall and cytoplasm detachment from the inner mem-
brane), the presence of flagella and vesicles were quanti-
fied. The experiments were performed twice.
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